The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

ViiV Healthcare’s long-acting Cabenuva for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges: London, UK Friday, February 20 ...

Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications MADISON ...